JP6590927B2 - ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド - Google Patents
ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド Download PDFInfo
- Publication number
- JP6590927B2 JP6590927B2 JP2017525907A JP2017525907A JP6590927B2 JP 6590927 B2 JP6590927 B2 JP 6590927B2 JP 2017525907 A JP2017525907 A JP 2017525907A JP 2017525907 A JP2017525907 A JP 2017525907A JP 6590927 B2 JP6590927 B2 JP 6590927B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- group
- alkyl
- acid
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C)OC(N*(*)c1n[o]c2c1C=CCC2)=O Chemical compound CC(C)(C)OC(N*(*)c1n[o]c2c1C=CCC2)=O 0.000 description 3
- HLBLARGAXQXQEF-UHFFFAOYSA-N CC(C)(C)OC(N1Cc(cccc2C(NC(C)(C)c3n[n](C)c4ccccc34)=O)c2OCC1)=O Chemical compound CC(C)(C)OC(N1Cc(cccc2C(NC(C)(C)c3n[n](C)c4ccccc34)=O)c2OCC1)=O HLBLARGAXQXQEF-UHFFFAOYSA-N 0.000 description 1
- YBNVFKDBVGFNHC-UHFFFAOYSA-N CC(C)(C)OC(NC(C)(C)C(NCc1c(C)cccn1)=O)=O Chemical compound CC(C)(C)OC(NC(C)(C)C(NCc1c(C)cccn1)=O)=O YBNVFKDBVGFNHC-UHFFFAOYSA-N 0.000 description 1
- XXHKALCUXSGPIL-UHFFFAOYSA-N CC(C)(C)OC(NC(C)(C)c1n[n](C)c2c1cccc2C)=O Chemical compound CC(C)(C)OC(NC(C)(C)c1n[n](C)c2c1cccc2C)=O XXHKALCUXSGPIL-UHFFFAOYSA-N 0.000 description 1
- LPVLVSXVCYLMQR-UHFFFAOYSA-N CC(C)(c1c(cccc2)c2cc(C)n1)NC(c1cccc2c1OCCNC2)=O Chemical compound CC(C)(c1c(cccc2)c2cc(C)n1)NC(c1cccc2c1OCCNC2)=O LPVLVSXVCYLMQR-UHFFFAOYSA-N 0.000 description 1
- KRGAYCPFSCFSOW-UHFFFAOYSA-N CC(C)(c1n[n](C)c2c1cccc2)NC(c1cccc2c1OCCNC2)=O Chemical compound CC(C)(c1n[n](C)c2c1cccc2)NC(c1cccc2c1OCCNC2)=O KRGAYCPFSCFSOW-UHFFFAOYSA-N 0.000 description 1
- HTGFIESAOUOIKJ-UHFFFAOYSA-N CC(C)(c1ncnc2c1cccc2)NC(c1cccc2c1OCCNC2)=O Chemical compound CC(C)(c1ncnc2c1cccc2)NC(c1cccc2c1OCCNC2)=O HTGFIESAOUOIKJ-UHFFFAOYSA-N 0.000 description 1
- QBQJAORHDBONOD-UHFFFAOYSA-N c(nc1)c2[n]1cccc2-c1c(cccn2)c2ccc1 Chemical compound c(nc1)c2[n]1cccc2-c1c(cccn2)c2ccc1 QBQJAORHDBONOD-UHFFFAOYSA-N 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N c1c(cccc2)[n]2nc1 Chemical compound c1c(cccc2)[n]2nc1 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N c1cnc(cncc2)c2c1 Chemical compound c1cnc(cncc2)c2c1 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- LKZHLVUXXMVVRI-UHFFFAOYSA-N c1cnc2[n]1cccc2-c1cncc2c1cccc2 Chemical compound c1cnc2[n]1cccc2-c1cncc2c1cccc2 LKZHLVUXXMVVRI-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N c1n[nH]c2ccccc12 Chemical compound c1n[nH]c2ccccc12 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N c1n[o]c2c1cccc2 Chemical compound c1n[o]c2c1cccc2 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193182.4 | 2014-11-14 | ||
| EP14193182 | 2014-11-14 | ||
| PCT/EP2015/076439 WO2016075239A1 (en) | 2014-11-14 | 2015-11-12 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533935A JP2017533935A (ja) | 2017-11-16 |
| JP2017533935A5 JP2017533935A5 (enExample) | 2018-12-27 |
| JP6590927B2 true JP6590927B2 (ja) | 2019-10-16 |
Family
ID=51904764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525907A Active JP6590927B2 (ja) | 2014-11-14 | 2015-11-12 | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10183940B2 (enExample) |
| EP (1) | EP3218371B1 (enExample) |
| JP (1) | JP6590927B2 (enExample) |
| WO (1) | WO2016075239A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
| WO2021233428A1 (zh) * | 2020-05-21 | 2021-11-25 | 广州费米子科技有限责任公司 | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
| CN112552303B (zh) * | 2020-12-14 | 2021-11-30 | 承德医学院 | 嘧啶酮并二氮杂卓类化合物及其盐、其制备方法及医药用途 |
| AR127055A1 (es) | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
| WO2025247982A1 (en) | 2024-05-29 | 2025-12-04 | Grünenthal GmbH | Piperazines which act as sstr4 modulators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3497164B2 (ja) * | 1991-06-28 | 2004-02-16 | スミスクライン・ビーチャム・コーポレイション | 二環式フィブリノーゲン拮抗薬 |
| ATE309993T1 (de) | 1997-04-21 | 2005-12-15 | Takeda Pharmaceutical | 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten |
| JPH11209356A (ja) * | 1997-04-21 | 1999-08-03 | Takeda Chem Ind Ltd | 縮合環化合物、その製造法及び剤 |
| ATE438624T1 (de) * | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US8247403B2 (en) | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| KR20110036044A (ko) * | 2008-07-18 | 2011-04-06 | 다케다 파머수티컬 컴패니 리미티드 | 벤즈아제핀 유도체들 및 히스타민 ｈ3 길항제로서 이들의 용도 |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| WO2012164085A1 (en) * | 2011-06-03 | 2012-12-06 | Merz Pharma Gmbh & Co. Kgaa | Glycine b antagonists |
| JP2013189395A (ja) * | 2012-03-14 | 2013-09-26 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロピロロピラジノン誘導体 |
| TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| CN103497181B (zh) * | 2013-09-30 | 2016-03-30 | 承德医学院 | 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途 |
-
2015
- 2015-11-12 WO PCT/EP2015/076439 patent/WO2016075239A1/en not_active Ceased
- 2015-11-12 US US15/526,360 patent/US10183940B2/en active Active
- 2015-11-12 JP JP2017525907A patent/JP6590927B2/ja active Active
- 2015-11-12 EP EP15793839.0A patent/EP3218371B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180291018A1 (en) | 2018-10-11 |
| JP2017533935A (ja) | 2017-11-16 |
| EP3218371B1 (en) | 2018-09-26 |
| WO2016075239A1 (en) | 2016-05-19 |
| US10183940B2 (en) | 2019-01-22 |
| EP3218371A1 (en) | 2017-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102286196B1 (ko) | 신규한 소마토스타틴 수용체 아형 4(sstr4) 작용제 | |
| CN107108592B (zh) | 吗啉和1,4-氧氮杂环庚烷酰胺作为抑生长素受体亚型4(sstr4)激动剂 | |
| JP2013534235A (ja) | ２−（アリールアミノ）−３ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボキサミド誘導体およびｍｐｇｅｓ−１阻害剤としてのこれらの使用 | |
| JP6590927B2 (ja) | ソマトスタチン受容体サブタイプ４（ｓｓｔｒ４）作動薬としてのアリール及びヘテロアリール縮合テトラヒドロ−１，４−オキサゼピンアミド | |
| KR102293386B1 (ko) | 신규한 (시아노-디메틸-메틸)-이속사졸 및 -[1,3,4]티아디아졸 | |
| HK1222850B (en) | New somatostatin receptor subtype 4 (sstr4) agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190819 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190815 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190917 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6590927 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |